AKT1 and Parkinson disease: To establish a drug-screening system using impaired mitochondrial clearance in PD iPSCs, we used two healthy controls, two PARK2 (Parkin-Ex2-4 homozygous deletion; PA and Parkin-Ex6, 7 homozygous deletion; PB), and one PARK6 (PINK1-c.1162T>C heterozygous mutation; PKB) iPSCs to derive dopaminergic neurons.